-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 6, local time, Merck & Co.
(MSD) announced that the U.
S.
Food and Drug Administration (FDA) has accelerated the approval of its anti-PD-1 therapy Keytruda and trastuzumab and fluoropyrimidine and platinum-based chemotherapy Combined, the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma patients.
Gastric carcinoma is a malignant tumor that originates from the epithelium of the gastric mucosa.
According to statistics, in 2020, there will be 480,000 newly diagnosed gastric cancer patients in my country, and 370,000 patients will die of gastric cancer! However, due to the limited effectiveness of the first-line therapy of "chemotherapy", the 5-year survival rate for patients with advanced or metastatic gastric cancer is only 5%.
Therefore, the development of new therapies for gastric cancer is imminent.
It is reported that the accelerated approval of this therapy is currently the first anti-PD-1 therapy approved for use in combination with trastuzumab and chemotherapy.
It is also another major breakthrough after Bristol-Myers Squibb's (BMS) PD-1 inhibitor Opdivo combined with chemotherapy was approved for the treatment of gastric cancer patients.
The therapy mainly blocks the interaction of PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes to enhance the human immune system's ability to detect and destroy cancer cells.
It is understood that this accelerated approval is based on the support of an ongoing randomized double-blind, placebo-controlled clinical trial KEYNOTE-811.
The results of the interim analysis showed that of the 264 patients initially randomized into the group, the overall response rate (ORR) of the Keytruda combination therapy group reached 74%, which was significantly better than the control group composed of placebo, trastuzumab and chemotherapy (52 %).
In the future, it is expected that more new products will usher in the field of gastric cancer treatment.
End reference material: [1]The selected onlookers dinner in the past exceeds 6 o'clock, so please don't eat these foods! How long does the new crown vaccine work? Science published an article revealing: May be affected by the difference in age and B cell memory in tissues.
Rewen wants to lose weight but always can't control it? Nature sub-publishes reveal: Why do some people always eat so much hungry fast.
New article Cell reveals: Prevent brain aging, reverse dementia, or can enhance neuronal autophagy to achieve this.
Still not quit smoking? BMJ sub-news reveal: the harm of second-hand smoke is beyond your imagination.
Pharmaceutical immunotherapy | biosimilars | vaccines | drug resistance | drug targets | healthy life | pharmaceutical company news | drug inventory | pharmaceutical technology | basic research on drug side effects /Translational Medicine Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbial Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing| Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anticancer drugs | 4+7 volume procurement | Consumables | Record system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical devices | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
(MSD) announced that the U.
S.
Food and Drug Administration (FDA) has accelerated the approval of its anti-PD-1 therapy Keytruda and trastuzumab and fluoropyrimidine and platinum-based chemotherapy Combined, the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma patients.
Gastric carcinoma is a malignant tumor that originates from the epithelium of the gastric mucosa.
According to statistics, in 2020, there will be 480,000 newly diagnosed gastric cancer patients in my country, and 370,000 patients will die of gastric cancer! However, due to the limited effectiveness of the first-line therapy of "chemotherapy", the 5-year survival rate for patients with advanced or metastatic gastric cancer is only 5%.
Therefore, the development of new therapies for gastric cancer is imminent.
It is reported that the accelerated approval of this therapy is currently the first anti-PD-1 therapy approved for use in combination with trastuzumab and chemotherapy.
It is also another major breakthrough after Bristol-Myers Squibb's (BMS) PD-1 inhibitor Opdivo combined with chemotherapy was approved for the treatment of gastric cancer patients.
The therapy mainly blocks the interaction of PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes to enhance the human immune system's ability to detect and destroy cancer cells.
It is understood that this accelerated approval is based on the support of an ongoing randomized double-blind, placebo-controlled clinical trial KEYNOTE-811.
The results of the interim analysis showed that of the 264 patients initially randomized into the group, the overall response rate (ORR) of the Keytruda combination therapy group reached 74%, which was significantly better than the control group composed of placebo, trastuzumab and chemotherapy (52 %).
In the future, it is expected that more new products will usher in the field of gastric cancer treatment.
End reference material: [1]The selected onlookers dinner in the past exceeds 6 o'clock, so please don't eat these foods! How long does the new crown vaccine work? Science published an article revealing: May be affected by the difference in age and B cell memory in tissues.
Rewen wants to lose weight but always can't control it? Nature sub-publishes reveal: Why do some people always eat so much hungry fast.
New article Cell reveals: Prevent brain aging, reverse dementia, or can enhance neuronal autophagy to achieve this.
Still not quit smoking? BMJ sub-news reveal: the harm of second-hand smoke is beyond your imagination.
Pharmaceutical immunotherapy | biosimilars | vaccines | drug resistance | drug targets | healthy life | pharmaceutical company news | drug inventory | pharmaceutical technology | basic research on drug side effects /Translational Medicine Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbial Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing| Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anticancer drugs | 4+7 volume procurement | Consumables | Record system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical devices | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
